Inactive Instrument

News Quest PharmaTech Inc. Other OTC

Stocks

QPTFF

CA74836M1068

Biotechnology & Medical Research

All News

31/05	Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2026	CI
30/05	Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	CI
30/05	Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis	AQ
23/12	Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2025	CI
27/25/27	Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2025	CI
28/25/28	Quest PharmaTech Announces Results from AGM	AQ
28/25/28	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2025	CI
11/25/11	Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech	AQ
03/25/03	Quest PharmaTech Provides Corporate Update	AQ
29/25/29	Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2025	CI
28/25/28	Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	CI
23/24/23	Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2024	CI
12/24/12	Quest PharmaTech Announces Results from AGM	AQ
23/24/23	Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2024	CI
28/24/28	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
31/24/31	Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director	AQ
31/24/31	Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	CI
30/24/30	Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	CI
29/24/29	Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	CI
31/24/31	Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	MT
31/24/31	Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	MT
31/24/31	Quest Receives Cash Dividend Payment from OncoQuest	AQ
24/24/24	Quest PharmaTech Inc. - Oregovomab Phase III Clinical Study fails futility analysis, Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits	AQ
24/24/24	Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits	AQ
24/24/24	Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study	CI